Skip to main content
Log in

Hormonal and temperature responses to the 5-HT1A receptor agonist flesinoxan in normal volunteers

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale. Flesinoxan is a highly potent and selective 5-HT1A agonist and appears to be a potentially interesting neuroendocrine serotonergic probe.

Objectives. We assessed hormonal (ACTH, cortisol, prolactin and growth hormone) and temperature responses to flesinoxan in normal volunteers.

Methods. In a double-blind placebo-controlled study, single doses of 0.5 mg and 1 mg were injected over 10 min into 12 healthy male volunteers at 1-week intervals. Temperature and hormonal responses were measured at times –30, 0, 15, 30, 60, 90, and 120 min.

Results. Flesinoxan induced a significant and dose-dependent increase in adrenocorticotropic hormone (ACTH), cortisol, prolactin (PRL), growth hormone (GH) and a decrease in body temperature. Tolerance to flesinoxan was excellent.

Conclusions. These results showed the role of 5-HT1A mechanisms in the PRL, ACTH, cortisol, GH, and temperature responses to flesinoxan. In the present study, flesinoxan appears a very promising serotonergic neuroendocrine probe.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Electronic Publication

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pitchot, W., Wauthy, J., Hansenne, M. et al. Hormonal and temperature responses to the 5-HT1A receptor agonist flesinoxan in normal volunteers. Psychopharmacology 164, 27–32 (2002). https://doi.org/10.1007/s00213-002-1177-0

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-002-1177-0

Navigation